Metastatic Biliary Tract Cancer
Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2025
2026
2027
2028
2029
2030
2031
Compass TherapeuticsGemcitabine
CurisEmavusertib
Clinical Trials (2)
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
Start: Jan 2025Est. completion: May 2029
Phase 1/2Recruiting
Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Start: Feb 2026Est. completion: Apr 2032
Phase 1Not Yet Recruiting
Related Jobs in Oncology
Cell Therapy Account Manager（北陸）
Gilead Sciences
Japan - Tokyo
Just now
Senior Director of Clinical Operations
Arvinas
Remote
1h ago
Specialist, Quality Assurance
Umoja Biopharma
Louisville, Colorado, United States
3h ago
$85K - $105K/yr
Senior Facilities Technician
Umoja Biopharma
Louisville, Colorado, United States
3h ago
Leo Cancer Care: Senior In-House Counsel/General Counsel
Leo Cancer Care
Middleton, Wisconsin
7h ago
Summer Intern - Computational Chemistry & Artificial Intelligence
Arvinas
Remote
8h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials
Small Molecule is the dominant modality (100% of programs)
2 companies competing in this space